Dr Adam Bryant

Dr Adam Bryant

Conjoint Senior Lecturer
Medicine & Health
School of Clinical Medicine

Adam is a Senior Staff Specialist Haematologist at Liverpool Hospital in South Western Sydney. He is Chair of the region’s Myeloma and Plasma Cell Disorders Unit through which he and his colleagues are responsible for a large practice of patients with myeloma and related diseases. Adam has been the Principal Investigator of numerous myeloma clinical trials and is an active member of the Myeloma Working Party of the Australia Leukaemia and Lymphoma Group (ALLG). Adam’s other specific subspecialty interest is in Stem Cell Transplantation and Cellular Therapies, having been a founding member of the SW Sydney Allogeneic BMT program which commenced in 2012.
Adam is current Treasurer and NSW Councillor of the Haematology Society of Australia and New Zealand, which is involved in advocacy and education on behalf of haematologists across the region. Closer to home, he is also the Chair of the rapidly expanding Haematology Clinical Trials Unit of South Western Sydney, an entity whose mantra is to bring new and innovative therapies to a historically under resourced and underprivileged region. He has had various other roles, in particular as the former Chair of the EviQ Haematology Reference Committee, as a journal reviewer and as a presenter and editorial contributor to Australian myeloma education through organisations including Limbic, Research Review and Myeloma Australia.

Phone
02 8738 5167
Location
Liverpool Hospital
  • Book Chapters | 2021
    Bryant A, 2021, 'Elotuzumab', in Resistance to Targeted Anti-Cancer Therapeutics, Springer International Publishing, pp. 73 - 82, http://dx.doi.org/10.1007/978-3-030-73440-4_6
  • Journal articles | 2024
    Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Ribas de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Aparecida Martinez G; Sureda Balarí AM; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah A-O; Oriol A; Gatt ME; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; McKeown A; McNamara S; Zhou X; Nichols M; Lewis E; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos M-V; DREAMM-7 Investigators , 2024, 'Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.', N Engl J Med, http://dx.doi.org/10.1056/NEJMoa2405090
    Journal articles | 2024
    Tong MH; Kwok A; Walsh A; Heydon P; Koh ES; McNamara N; Bryant A, 2024, 'Isolated Ocular Relapse of Acute Myeloid Leukaemia Post Allogeneic Stem Cell Transplant.', Case Rep Ophthalmol Med, 2024, pp. 2235819, http://dx.doi.org/10.1155/2024/2235819
    Journal articles | 2023
    Li E; Bryant C; Jones E; King T; Talaulikar D; Ng J; Bryant A; Ridha Z; Doo NW; Ling S; Ho PJ; Joshua D, 2023, 'P-289 The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy', Clinical Lymphoma Myeloma and Leukemia, 23, pp. S196 - S196, http://dx.doi.org/10.1016/s2152-2650(23)01907-9
    Journal articles | 2023
    Plesner T; Harrison SJ; Quach H; Lee C; Bryant A; Vangsted A; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Ruppert SM; Sumiyoshi T; Miller K; Cho E; Schjesvold F, 2023, 'Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma', Clinical Hematology International, 5, pp. 43 - 51, http://dx.doi.org/10.1007/s44228-022-00023-5
    Journal articles | 2023
    Ponraj R; Bryant A; Dunlop L; Range H; Cobrador C; Ling S; Hsu D, 2023, 'Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA', Blood Cancer Journal, 13, http://dx.doi.org/10.1038/s41408-023-00885-9
    Journal articles | 2021
    McCaughan GJ; Verma A; Ling S; Lavee O; Moore JJ; Bryant A, 2021, 'Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres', Bone Marrow Transplantation, 56, pp. 738 - 740, http://dx.doi.org/10.1038/s41409-020-01086-9
    Journal articles | 2020
    Othman J; Greenwood M; Moore J; Larsen S; Watson AM; Arthur C; Bhattacharyya A; Bilmon I; Blyth E; Bryant A; Bryant C; Dunlop L; Fay K; Gibson J; Hamad N; Kerridge I; Kwan J; Ma D; Micklethwaite K; Milliken S; Panicker S; Stevenson W; Withers B; Wilcox L; Tran S; Gottlieb DJ, 2020, 'Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG', Biology of Blood and Marrow Transplantation, 26, pp. 1868 - 1875, http://dx.doi.org/10.1016/j.bbmt.2020.06.030
    Journal articles | 2014
    Bilmon I; Nivison-Smith I; Hertzberg M; Ritchie D; Greenwood M; Spencer A; Kennedy G; Bryant A; Moore J, 2014, 'Outcomes following second allogeneic haematopoietic transplants using fludarabine–melphalan conditioning', Bone Marrow Transplantation, 49, pp. 852 - 853, http://dx.doi.org/10.1038/bmt.2014.23
    Journal articles | 2014
    Bryant A; Nivison-Smith I; Pillai ES; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil S; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearing R; Moore J, 2014, 'Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients', Bone Marrow Transplantation, 49, pp. 17 - 23, http://dx.doi.org/10.1038/bmt.2013.142
    Journal articles | 2014
    Dalal BI; Al Mugairi A; Pi S; Lee SY; Khare NS; Pal J; Bryant A; Vakil AP; Lau S; Abou Mourad YR, 2014, 'Aberrant expression of CD13 identifies a subgroup of standard-risk adult acute lymphoblastic leukemia with inferior survival.', Clin Lymphoma Myeloma Leuk, 14, pp. 239 - 244, http://dx.doi.org/10.1016/j.clml.2013.10.003
    Journal articles | 2014
    Palma CA; Al Sheikha D; Lim TK; Bryant A; Vu TT; Jayaswal V; Ma DDF, 2014, 'MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia', Molecular Cancer, 13, http://dx.doi.org/10.1186/1476-4598-13-79
    Journal articles | 2012
    Bryant A; Palma CA; Jayaswal V; Yang YH; Lutherborrow MA; Ma DD, 2012, 'miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death', Molecular Cancer, 11, pp. 8, http://dx.doi.org/10.1186/1476-4598-11-8
    Journal articles | 2011
    Bryant AJ; Palma CA; Lutherborrow M; Jayaswal V; Yang YH; Ma D, 2011, 'Knockdown of MicroRNA-10a in Acute Myeloid Leukaemia Cells Bearing the Nucleophosmin1 Mutation Causes Cell Death and Reduced Clonogenicity', Blood, 118, pp. 1367 - 1367, http://dx.doi.org/10.1182/blood.v118.21.1367.1367
    Journal articles | 2011
    Bryant AJ; Pillai E; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil SS; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearling R; Nivison-Smith I; Moore J, 2011, 'A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998–2008,', Blood, 118, pp. 4143 - 4143, http://dx.doi.org/10.1182/blood.v118.21.4143.4143
    Journal articles | 2011
    Palma CA; Tonna E; Bryant AJ; Jayaswal V; Agapiou D; Yang YH; Ma D; Lutherborrow M, 2011, 'MicroRNA Expression in Acute Myeloid Leukaemia and Their Effects on the Differentiation of Acute Myeloid Leukaemia Cells', Blood, 118, pp. 2430 - 2430, http://dx.doi.org/10.1182/blood.v118.21.2430.2430
    Journal articles | 2010
    Sasson SC; Smith S; Seddiki N; Zaunders J; Bryant AJ; Koelsch KK; Weatherall CJ; Munier CM; McGinley C; Yeung J; Mulligan S; Moore JJ; Cooper DA; Milliken ST; Kelleher AD, 2010, 'IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers', Cytokine, 50, pp. 58 - 68
    Journal articles | 2006
    Bryant A; Moore J, 2006, 'Rituximab and its potential for the treatment of rheumatoid arthritis', Therapeutics and Clinical Risk Management, 2, pp. 207 - 212, http://dx.doi.org/10.2147/tcrm.2006.2.2.207
  • Conference Abstracts | 2023
    Bryant C; Abadir E; Doo NW; Bryant A; McCaughan G; Yang S; Vanguru V; King T; Joshua D; Ho PJ, 2023, 'P-070 Failure to clear circulating tumor cells after one week of daratumumab, bortezomib and dexamethasone is associated with a reduced progression-free survival for myeloma patients', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 23, pp. S73 - S73, http://dx.doi.org/10.1016/s2152-2650(23)01688-9
    Conference Papers | 2021
    Plesner T; Harrison SJ; Quach H; Lee CH; Bryant A; Vangsted AJ; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Sumiyoshi T; Miller K; Choi E; Schjesvold FH, 2021, 'A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)', in BLOOD, AMER SOC HEMATOLOGY, http://dx.doi.org/10.1182/blood-2021-147418Get
    Conference Abstracts | 2021
    Plesner T; Harrison SJ; Quach H; Lee CH; Bryant A; Vangsted AJ; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Sumiyoshi T; Miller K; Choi E; Schjesvold FH, 2021, 'A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)', in Blood, American Society of Hematology, Vol. 138, pp. 2755 - 2755, http://dx.doi.org/10.1182/blood-2021-147418
    Conference Abstracts | 2020
    McCaughan GJ; Tran S; Durrant S; Harrison SJ; Morton J; Horvath N; Spencer A; Kerridge IH; Er JAK; Barge L; Bryant A; Filshie RJ; Choong E; Lai HC; Tiley C; Mills AK; Butler A; Moore J; Hertzberg M; Kennedy GA; Ho PJ; Sidiqi MH; Bashford J; Routledge D; Taylor K; Lee CH; Kalff A; Xia W; Hamad N, 2020, 'Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study', in Blood, American Society of Hematology, Vol. 136, pp. 11 - 12, http://dx.doi.org/10.1182/blood-2020-138991
    Conference Abstracts | 2020
    McCaughan GJ; Verma A; Ling S; Lavee O; Moore J; Bryant A, 2020, 'Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres', in Blood, American Society of Hematology, Vol. 136, pp. 42 - 43, http://dx.doi.org/10.1182/blood-2020-139269
    Conference Abstracts | 2019
    Haack R; Mallik S; Sungala N; Bryant A; Ho LL; Motum P, 2019, 'COPPER DEFICIENCY: DON'T YOU FORGET ABOUT ME.', in INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, WILEY, Vol. 41, pp. 68 - 68, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000487566000106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2016
    Watson A-M; Bryant A; Davison S; Ling S; Levy M, 2016, 'Treatment of Otherwise Ineligible Donors for Hepatitis B Prior to Matched Sibling Allogeneic Stem Cell Transplant', in BONE MARROW TRANSPLANTATION, NATURE PUBLISHING GROUP, SPAIN, Valencia, Vol. 51, pp. S140 - S140, presented at 42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, SPAIN, Valencia, 03 April 2016 - 06 April 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000373357600241&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2013
    Bryant A; Kershaw G; Zebeljan D; Motum P; Das R, 2013, 'Factor VIII inhibitor and pulmonary embolism developing in a patient after meningioma resection: clinical and laboratory aspects', in JOURNAL OF THROMBOSIS AND HAEMOSTASIS, WILEY-BLACKWELL, Vol. 11, pp. 1021 - 1021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000331833604400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2013
    Dalal BI; Al Mugairi A; Bryant A; Lau S; Pi S; Khare NS; Pal J; Mourad YA, 2013, 'Aberrant Expression of Myeloid Antigens Identifies a Subgroup of Standard-Risk Adult Acute Lymphoblastic Leukemia Patients with Short Survival', in Biology of Blood and Marrow Transplantation, Elsevier BV, Vol. 19, pp. S223 - S224, http://dx.doi.org/10.1016/j.bbmt.2012.11.268
    Conference Papers | 2011
    Bryant AJ; Palma CA; Lutherborrow M; Jayaswal V; Yang YH; Ma D, 2011, 'Knockdown of MicroRNA-10a in Acute Myeloid Leukaemia Cells Bearing the Nucleophosmin1 Mutation Causes Cell Death and Reduced Clonogenicity', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, pp. 599 - 600, presented at 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, CA, San Diego, 10 December 2011 - 13 December 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000299597101636&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2011
    Palma CA; Tonna E; Bryant AJ; Jayaswal V; Agapiou D; Yang YH; Ma D; Lutherborrow M, 2011, 'MicroRNA Expression in Acute Myeloid Leukaemia and Their Effects on the Differentiation of Acute Myeloid Leukaemia Cells', in Blood, American Society of Hematology, Vol. 118, pp. 2430 - 2430, http://dx.doi.org/10.1182/blood.v118.21.2430.2430

Please contact my unit using the email below for further information about active clinical trials at Liverpool and SWSLHD